The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 18 of the 64 sources its claims cite were checked for support.
Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum
Open accessAbstract
Top-down mass spectrometry (MS)-based proteomics provides a comprehensive analysis of proteoforms to achieve a proteome-wide understanding of protein functions. However, the MS detection of low-abundance proteins from blood remains an unsolved challenge due to the extraordinary dynamic range of the blood proteome. Here, we develop an integrated nanoproteomics method coupling peptide-functionalized superparamagnetic nanoparticles (NPs) with top-down MS for the enrichment and comprehensive analysis of cardiac troponin I (cTnI), a gold-standard cardiac biomarker, directly from serum. These NPs enable the sensitive enrichment of cTnI (<1 ng/mL) with high specificity and reproducibility, while simultaneously depleting highly abundant proteins such as human serum albumin (>10 10 more abundant than cTnI). We demonstrate that top-down nanoproteomics can provide high-resolution proteoform-resolved molecular fingerprints of diverse cTnI proteoforms to establish proteoform-pathophysiology relationships. This scalable and reproducible antibody-free strategy can generally enable the proteoform-resolved analysis of low-abundance proteins directly from serum to reveal previously unachievable molecular details.
Overview
CoChat Summary
TL;DR
The paper develops an antibody-free top-down nanoproteomics method that uses peptide-functionalized superparamagnetic nanoparticles to enrich cardiac troponin I (cTnI) directly from human serum and analyze its proteoforms by top-down mass spectrometry. The approach enriches cTnI while depleting highly abundant human serum albumin and detects cTnI proteoforms at clinically relevant low ng/mL levels.
Key findings
- The NP-Pep uses a 13-mer cTnI-binding peptide (HWQIAYNEHQWQC) with a reported Kd of 270 pM, targeting cTnI residues 114–144; peptide surface density was inferred as ~0.034 µmol peptide/mg NP, and NP-Pep zeta potential in 0.1× PBS was ~−38 mV.
- From human heart sarcomeric extracts, NP-Pep enriched cTnI over threefold (p < 0.0001) relative to the loading mixture and preserved endogenous cTnI proteoform distributions, including ppcTnI[1-207], cTnI, pcTnI, and ppcTnI.
- From human serum, NP-Pep enabled detection of cTnI proteoforms with an LOD of 0.75 ng/mL, while top-down MS alone detected purified cTnI with an LOD of 0.06 ng/mL; NP-Pep showed a 115-fold cTnI enrichment factor and ~51% serum cTnI recovery, compared with ~17% for Agarose-mAb.
- NP-Pep nearly completely depleted HSA, which is >10 orders of magnitude more abundant than circulating cTnI, and revealed proteoform fingerprints: donor hearts were primarily phosphorylated cTnI, dilated cardiomyopathy hearts showed decreased phosphorylated cTnI, and postmortem samples showed C-terminal truncated cTnI proteoforms.
Methods
- The authors synthesized BAPTES-silanized Fe3O4 nanoparticles and conjugated the cTnI-binding peptide via cysteine-thiol chemistry, characterizing NPs by TEM, FTIR, TGA, and zeta potential.
- cTnI enrichment was tested from human heart sarcomeric extracts and from human male AB serum spiked with cTnI from donor, dilated cardiomyopathy, and postmortem heart samples; NP-Pep was compared with agarose-peptide and anti-cTnI monoclonal antibody (M46) platforms.
- Enriched fractions were analyzed by SDS-PAGE, ELISA, and top-down LC/MS using reversed-phase liquid chromatography coupled to a maXis II Q-TOF mass spectrometer, with deconvolution and MS/MS for proteoform identification.
Limitations
- The paper states that some nonspecific proteins were still retained from serum enrichment, that cTnI recovery could be improved by automating the NP-Pep workflow to reduce sample handling and protein loss, and that further instrumentation improvements are needed to reach the diagnostic cutoff used by contemporary cTnI ELISA (≤0.04 ng/mL).
- The paper notes that the allene carboxamide chemistry relies on a Cys nonessential to the peptide binding sequence, with alternative bioorthogonal coupling approaches needed if such a Cys is unavailable.
- Evident from the text: serum experiments used spike-in cTnI from a limited set of human heart samples rather than endogenous circulating cTnI from a large patient cohort, so clinical validation remains future work.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Evaluation of enrichment performance and reproducibility of NP-Pep for capturing cTnI. a Schematic illustration of the nanoproteomics strategy for cTnI enrichment and top-down MS analysis of cTnI proteoforms. Heart tissue extract (loading mixture, L) is first incubated with the NP-Pep. Following magnetic isolation, the nonspecific proteins are removed as flow through (F). The NPs are washed and the NP-bound proteins of interest are eluted (E) and analyzed by top-down LC/MS. b SDS-PAGE demonstrates the high reproducibility obtained from three different NP-Pep syntheses (inter-batch). The lower panels highlight the specific enrichment of cTnI and cTnT in E as compared to L and F. Evaluation of total cTnI proteoform recovery (c), and relative abundance of cTnI (d), before and after NP-Pep enrichment. The same L, F, and E shown in the SDS-PAGE from (b) were equally loaded (500 ng) for LC/MS analysis. The deconvoluted top-down mass spectra corresponding to cTnI proteoforms were used to calculate the relative abundance of each cTnI proteoform when normalizing for total protein amount injected. Proteoform abundance data (c) are representative of n = 6 independent experiments with error bars indicating standard error of the mean. cTnI relative abundance data (d) are representative of n = 3 independent experiments with error bars indicating standard error of the mean. e MS-based evaluation of cTnI enrichment using three different synthetic batches of NP-Pep showing the reproducible enrichment performance. f–h Enrichment from three different human heart samples using NP-Pep in comparison with agarose-mAb. Upper panels feature SDS-PAGE strips that visualize cTnI enrichment performance of NP-Pep and agarose-mAb. Equal protein amount (500 ng) of the L, F, and E was loaded on the gel in (b, f–h). Roman numerals correspond to N-terminally acetylated cTnI proteoforms following Met exclusion: (i) ppcTnI[1-207]; (ii) cTnI; (iii) pcTnI; (iv) ppcTnI; (v) cTnI[1-205]; (vi) pcTnI[1-205]; (vii) cTnI[1-206]; (viii) pcTnI[1-206]. M. protein marker, Std. endogenous cTnI protein standard, p phosphorylation, pp bisphosphorylation. A summary of the enriched proteoforms and their respective mass measurements by top-down MS are listed in Supplementary Tables 5 and 6. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/e4d74a24680844859a18d05228591cd5/nanoproteomics-enables-proteoform-resolved-analysis-of-low-abundance-proteins-in-figure-2.jpg)


Verification
Claims the paper makes
7 Valid · 0 Not valid · 16 Not checked · 50 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, the intrinsic challenge of designing and evaluating epitope-specific antibodies for PTMs makes it difficult to develop robust antibodies suitable for proteoform analysis16.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Introduction
What the sources say
- Partly supportedcites [16] Janes, K. A. Fragile epitopes—antibody’s guess is as good as yours. Sci. Signal.13, eaaz8130 (2020). sourceExperimental — accuracy not yet measured
The paper’s Abstract describes how a posttranslational modification can perturb antibody binding, and its discussion of PP2A C reports that phosphorylation or methylation made several antibodies unsuitable for particular assays. It also describes epitope recognition and antibody selection as difficult to predict. It does not specifically address developing PTM-specific antibodies for proteoform analysis, so that application extends beyond what the paper says. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the MS detection of low-abundance proteins remains an unsolved challenge due to high dynamic range of the human proteome8–10.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Introduction
What the sources say
- Partly supportedcites [8] Chen, B., Brown, K. A., Lin, Z. & Ge, Y. Top-down proteomics: ready for prime time? Anal. Chem.90, 110–127 (2018). sourceExperimental — accuracy not yet measured
Our copy does support the core of the claim: the Concluding Remarks list 'detection and characterization of high MW and low-abundance proteins' among on-going challenges that 'remain to be further addressed by novel methodologies', and the Sample Preparation and Data Acquisition sections describe low-abundance proteoforms being 'overwhelmed by the signals of co-eluting non-phosphorylated proteins' or 'hindered or missed entirely' because abundant precursors dominate DDA selection. What the source does not support is the stated cause and context: it never attributes the difficulty to the extraordinary dynamic range of the human (or blood) proteome — its only dynamic-range statements concern instrument response ('for intact proteins, the dynamic range and the instrument response greatly vary among instrument types', Quantitative Top-Down Proteomics) and note that instrumentation advances have given top-down 'wider dynamic range'. Blood/plasma appears only incidentally (Cheon et al.'s low-MW plasma proteome comparison, Applications > Global profiling), not as a proteome-wide dynamic-range obstacle. (LLM, conf=0.75)
- Not checked yetcites [9] Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24, 971–983 (2006). source
- Not checked yetcites [10] Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic. Prospects1, 845–867 (2002).
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent studies have shown that cTnI is heavily modified and its proteoforms arising from various PTMs can provide new insights to the molecular mechanisms underlying cardiovascular diseases27–31.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Introduction
What the sources say
- Supportedcites [27] Soetkamp, D. et al. The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform. Expert Rev. Proteomics14, 973–986 (2017). source
The 'Posttranslational Modifications as compensatory mechanisms and potential biomarkers' section says cTnI undergoes extensive PTMs and that altered PTM profiles can reflect dysregulated cellular signaling during cardiac disease. The Conclusion describes analysis of modified cTnI proteoforms as revealing a molecular fingerprint of myocardial health. These passages support the claim's potential for mechanistic insight; no page numbers are supplied in our copy. (LLM, conf=0.90)
- Not checked yetcites [28] Labugger, R., Organ, L., Collier, C., Atar, D. & Van Eyk, J. E. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation102, 1221–1226 (2000). source
- Not checked yetcites [29] Murphy, A. M. et al. Transgenic mouse model of stunned myocardium. Science287, 488–491 (2000). source
- Supportedcites [30] Peng, Y. et al. Top-down proteomics reveals concerted reductions in myofilament and Z-disc protein phosphorylation after acute myocardial infarction. Mol. Cell. Proteomics13, 2752–2764 (2014). source
The Results (page unavailable) identify distinct phosphorylated cTnI proteoforms and report reduced cTnI phosphorylation after acute myocardial infarction. The Discussion (page unavailable) connects cTnI phosphorylation to cardiac function and says that understanding these early molecular changes could inform interventions. Together, these passages support the hedged claim that studying cTnI proteoforms can provide insight into cardiovascular disease mechanisms. (LLM, conf=0.88)
- Partly supportedcites [31] Dong, X. et al. Augmented phosphorylation of cardiac troponin I in hypertensive heart failure. J. Biol. Chem.287, 848–857 (2012). sourceExperimental — accuracy not yet measured
The introduction (p. 2) says studying endogenous cTnI modifications in heart-failure models is important for understanding regulation of cardiac dysfunction. The discussion (p. 8) says mapping phosphorylation across multiple cTnI sites is crucial to understanding phosphorylation in cardiac disease. The paper supports the value of studying cTnI phosphorylation, but does not establish the broader claim about proteoforms arising from various kinds of PTMs across cardiovascular diseases. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Front-end protein enrichment strategies are therefore required to specifically capture and enrich low-abundance proteins from the complex biological milieu prior to MS analysis9,11.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Introduction
What the sources say
- Not checked yetcites [9] Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24, 971–983 (2006). source
- Supportedcites [11] Xie, S., Moya, C., Bilgin, B., Jayaraman, A. & Walton, S. P. Emerging affinity-based techniques in proteomics. Expert Rev. Proteomics6, 573–583 (2009). source
The Affinity Prefractionation section states that affinity-based separation methods are useful for enrichment of low abundance proteins in complex samples and reducing sample complexity, and that the high specificity between bait and capture molecule minimizes non-specific capture — matching 'specifically capture and enrich low-abundance proteins'. The necessity framing is echoed in the Abstract ('no single technique is adequate', limitations drive complementary methods for greater dynamic range/specificity) and Current Proteomics Methods (MS 'unlikely... stand-alone'; serum concentration range spans at least five orders of magnitude), with pre-MS separation/fractionation discussed throughout. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These serum cTnI enrichment results illustrate the major benefits of functionalized NPs compared to current antibody-based approaches: (1) NPs are capable of reproducibly and effectively enriching cTnI (Supplementary Fig. 23) across all tested serum samples without the use of antibody, thus overcoming the intrinsic antibody-related limitations (vide supra)14,15,51–53.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Results > Enrichment of low-abundance proteoforms from human serum
What the sources say
- Partly supportedcites [14] Baker, M. Reproducibility crisis: blame it on the antibodies. Nature521, 274–276 (2015). sourceExperimental — accuracy not yet measured
Baker (2015) supports only the 'intrinsic antibody-related limitations' half of the attributed clause: BLAME IT ON THE ANTIBODIES (p. 1) states antibodies are 'among the most common causes of problems', with batch-to-batch variability producing 'dramatically differing results' and antibodies recognizing extra proteins; VARIABILITY and CROSS-REACTIVITY sidebars (p. 3) and 'ANTIBODIES ARE NOT MAGIC REAGENTS' (p. 2) add missing validation/lot-to-lot data and up to half of commercial antibodies being unreliable. However, our copy says nothing about nanoparticles, an NP-Pep conjugate, or reproducible enrichment of cardiac troponin I (cTnI) in serum — searched 'cardiac troponin I enrichment nanoparticle peptide serum' with no relevant passage — so the experimental claim that NPs reproducibly and effectively enrich cTnI across all tested serum samples without antibody is the citing authors' own result and is not attributable to this news feature. (LLM, conf=0.75)
- Partly supportedcites [15] Bradbury, A. & Plückthun, A. Reproducibility: standardize antibodies used in research. Nature518, 27–29 (2015). sourceExperimental — accuracy not yet measured
Our copy of the Bradbury/Plückthun Nature commentary fully substantiates the 'intrinsic antibody-related limitations' clause the citation cluster is attached to: it reports that fewer than half of ~6,000 routinely used commercial antibodies recognized only their specified targets (C, p.1), that polyclonal functionality varies batch to batch with only 0.5-5% of antibodies binding the intended target and that hybridoma lines can die off or lose their antibody genes (WILDLY VARIABLE, p.1), and that only 44% of publications give enough information to repurchase the same antibody. However, nothing in our copy addresses the NP-Pep/nanoparticle-peptide result itself — reproducibly and effectively enriching cTnI across tested serum samples is the citing authors' own data (their Supplementary Fig. 23), and the paper mentions only other non-antibody reagent classes (recombinant protein scaffolds, nucleic-acid-based reagents/aptamers; TWO STEPS, p.2), not nanoparticles or cardiac troponin enrichment in serum. (LLM, conf=0.72)
- Not checked yetcites [51] Apple, F. S. Counterpoint: standardization of cardiac troponin I assays will not occur in my lifetime. Clin. Chem.58, 169–171 (2012). source
- Not checked yetcites [52] Apple, F. S., Sandoval, Y., Jaffe, A. S. & Ordonez-Llanos, J. Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care. Clin. Chem.63, 73–81 (2017). source
- Could not verifycites [53] Herman, D. S., Kavsak, P. A. & Greene, D. N. Variability and error in cardiac troponin testing: an ACLPS critical review. Am. J. Clin. Pathol.148, 281–295 (2017). sourceExperimental — accuracy not yet measured
Our copy of Herman et al. (2017, AJCP) is an ACLPS critical review of preanalytical, analytical and postanalytical error in cTn testing; no passage addresses nanoparticle or peptide-based, antibody-free enrichment of cTnI, nor any 'NP-Pep' construct (searched: nanoparticle/functionalized enrichment, mass spectrometry sample preparation, antibody-based limitations, cTnI serum enrichment). The closest material — the Interfering Antibodies section (heterophile and anti-cTn antibody interference, prevalence 5-20%, epitope-dependent assay effects) and the Lack of cTn Harmonization section — documents antibody-related assay problems but says nothing about a nanoparticle method reproducibly enriching cTnI across tested serum samples. Since our copy neither states nor contradicts the attributed experimental result, and it does not credit that result to any named work, the claim cannot be verified against this source. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
31 more claims · 1 with their cited sources checked
Create a free account to see all 73 claims and to verify the 46 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using the previously discussed NP-based method, Tiambeng and Roberts et al. demonstrated that different low-abundance cTnI proteoforms could be enriched directly from human serum and characterized by top-down MS, showing promise for improved clinical diagnosis [68].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“cardiac troponin I (cTnI) [65–67], an important and gold-standard cardiac biomarker [68].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the NP-peptide approach outperformed conventional monoclonal antibody and top-down characterization of cTnI, enriched from serum, yielded proteoform-resolved molecular fingerprints of diverse cTnI proteoforms for evaluation of proteoform-pathophysiology relationships (Figure 3) [68].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [68]
In the citing paper
“The NP-peptide approach enabled the enrichment of cTnI with high specificity (< 1 ng/mL) and reproducibility, while at the same time depleted highly abundant proteins like human serum albumin.”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [68]
In the citing paper
“Overall, the NP-peptide approach outperformed conventional monoclonal antibody and top-down characterization of cTnI, enriched from serum, yielded proteoform-resolved molecular fingerprints of diverse cTnI proteoforms for evaluation of proteoform-pathophysiology relationships (Figure 3) [68].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Methods > Comparison of cTnI enrichment from sarcomere extracts
“The methods described here correspond to the data presented in Fig. 2f–k and Supplementary Figs. 17 and 18.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Results > Reproducible and faithful recapitulation of cTnI proteoforms
“f–h Enrichment from three different human heart samples using NP-Pep in comparison with agarose-mAb.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Methods > Comparison of cTnI enrichment from serum spiked with cTnI
“The methods described here correspond to the data presented in Fig. 2a–d and Supplementary Figs. 20–22.”
§ Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum > Results > Reproducible and faithful recapitulation of cTnI proteoforms
“Heart tissue extract (loading mixture, L) is first incubated with the NP-Pep.”
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 2×
“Roman numerals correspond to N-terminally acetylated cTnI proteoforms following Met exclusion: (i) ppcTnI[1-207]; (ii) cTnI; (iii) pcTnI; (iv) ppcTnI; (v) cTnI[1-205]; (vi) pcTnI[1-205]; (vii) cTnI[1-206]; (viii) pcTnI[1-206].”
BackgroundNanostructures in Biodiagnostics
Rosi, N. L., & Mirkin, C. A. (2005) · Chemical Reviews · doi:10.1021/cr030067f · Cited by 4,603
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Ultra-large-scale syntheses of monodisperse nanocrystals
Park, J., An, K., Hwang, Y., Park, J.-G., Noh, H.-J., Kim, J.-Y., Park, J.-H., Hwang, N.-M., & Hyeon, T. (2004) · Nature Materials · doi:10.1038/nmat1251 · Cited by 4,076
Agard, N. J., Prescher, J. A., & Bertozzi, C. R. (2004) · Journal of the American Chemical Society · doi:10.1021/ja044996f · Cited by 3,017
Multifunctional Magnetic Nanoparticles: Design, Synthesis, and Biomedical Applications
Gao, J., Gu, H., & Xu, B. (2009) · Accounts of Chemical Research · doi:10.1021/ar9000026 · Cited by 1,907
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 2×
“Roman numerals correspond to N-terminally acetylated cTnI proteoforms following Met exclusion: (i) ppcTnI[1-207]; (ii) cTnI; (iii) pcTnI; (iv) ppcTnI; (v) cTnI[1-205]; (vi) pcTnI[1-205]; (vii) cTnI[1-206]; (viii) pcTnI[1-206].”
BackgroundWalkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Cited by
Roberts, D. S., Loo, J. A., Tsybin, Y. O., Liu, X., Wu, S., Chamot-Rooke, J., Agar, J. N., Paša-Tolić, L., Smith, L. M., & Ge, Y. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00318-2 · Cited by 161
Self-citationTop-down proteomics: challenges, innovations, and applications in basic and clinical research
Brown, K. A., Melby, J. A., Roberts, D. S., & Ge, Y. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1855982 · Cited by 152
Self-citationChapman, E. A., Roberts, D. S., Tiambeng, T. N., Andrews, J., Wang, M.-D., Reasoner, E. A., Melby, J. A., Li, B. H., Kim, D., Alpert, A. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43321-z · Cited by 28
Self-citation
Metadata
- Authors
- Tiambeng, T. N., Roberts, D. S., Brown, K. A., Zhu, Y., Chen, B., Wu, Z., Mitchell, S. D., Guardado-Alvarez, T. M., Jin, S., & Ge, Y.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Jin, Song
- Ge, Ying
- ORCID
- Venue
- Nature Communications
- Published
- 2020-08-06
- Volume
- 11
- Issue
- 1
- Pages
- 3903-3903
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7411019
- OpenAlex
- W3047360653
- Cited by
- 76
- References
- 63
- Citations by year
- 2026: 16 · 2025: 6 · 2024: 10 · 2023: 19 · 2022: 10 · 2021: 14 · 2020: 1
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL007936-19)
- U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD018475)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM117058, GM125085)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Keywords
- top-down mass spectrometry, low-abundance proteins, human serum, cardiac troponin I, cardiac biomarkers, superparamagnetic nanoparticles, peptide-functionalized nanoparticles, protein enrichment, proteoforms, cardiac pathophysiology
- MeSH terms
- Serum Albumin, Human, Blood Chemical Analysis, Blood Proteins, Humans, Protein Processing, Post-Translational, Mass Spectrometry, Reproducibility of Results, Biomarkers, Troponin I, Proteome, Nanotechnology, Proteomics, Magnetite Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum. https://app.cochat.ai/papers/10.1038/s41467-020-17643-1
- The paper
- Tiambeng, T. N., Roberts, D. S., Brown, K. A., Zhu, Y., Chen, B., Wu, Z., Mitchell, S. D., Guardado-Alvarez, T. M., Jin, S., & Ge, Y. (2020). Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum. Nature Communications. https://doi.org/10.1038/s41467-020-17643-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.